Frontlight ResearchEarly access
TerminatedPhase 2
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
Key facts
- Who runs it
- Guangxi Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 45 people enrolled
- Started
- 16 Feb 2025
- Ended
- 31 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Cadonilimab (AK104)
- Record updated
- 18 February 2026
- Why it stopped
- The support from the relevant company was not obtained as planned
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Sign a written informed consent before the implementation of any trial-related procedures
- Male or female, aged ≥18 years and ≤70 years
- ECOG PS score is 0 - 1 point
- Subjects diagnosed with hepatocellular carcinoma by imaging criteria and/or pathology and who have received curative resection
- The definition of curative resection complies with the definition of curativeness in the 2024 edition of the Chinese Guidelines for Primary Liver Cancer (CNLC)
- The postoperative recurrence risk stratification conforms to the high - risk group in the ERASL - pre or ERASL - post formula
- No prior systemic antitumor treatment for hepatocellular carcinoma has been received
- Child - Pugh liver function score of grade A or B7
- Expected survival time > 6 months
Who cannot take part
- Previously diagnosed by histology/cytology, including fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, etc
- Subjects with other malignant tumors within 5 years before enrollment, except for HCC. Subjects with other malignant tumors that have been cured by local treatment are not excluded, such as basal or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix or breast
- History of hepatic encephalopathy or liver transplantation
- Portal vein trunk or mesenteric superior vein, inferior vena cava tumor thrombus
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to compare the safety and tolerability of cadonilimab applied after curative hepatectomy for hepatocellular carcinoma combined with high - risk recurrent factors.
The group in the trial
- Treatment armTreatment being tested
Patients with hepatocellular carcinoma after curative hepatectomy would receive cadonilimab 10 mg/kg intravenous infusion (dissolved in 0.9% NaCl 250 mL, within 60 minutes) Q3W, until disease progression, death, intolerance to toxicity, withdrawal of informed consent, initiation of new anti-tumor treatment, or termination of treatment for other reasons specified in the protocol. The maximum treatment duration for cadonilimab is 6 months.
Treatment: Cadonilimab (AK104)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 18 February 2026